Journal:

Article Title: Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

doi:

Figure Lengend Snippet: Distribution of MICs reported by eight participating facilities each testing two control strains on 10 separate days

Article Snippet: For most drugs, the 48-h MICs were approximately one doubling concentration greater than those recorded after 24 h. Every effort was made to select MIC ranges that included at least 95% of the recorded values and that occasionally required a four-dilution range around a clearcut mode. table ft1 table-wrap mode="anchored" t5 caption a7 Antifungal agent and control strain a Incubation time (h) No. of times the following MICs (μg/ml) were reported ( n = 240) b : ≤0.016 0.03 0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16 32 64 128 Amphotericin B C. parapsilosis 24 7 [1 120 109 3] 48 20 [1 88 123 8] C. krusei 24 [2 141 97] 48 [10 202 28] Flucytosine C. parapsilosis 24 [43 c 152 43] 1 1 48 4 c [12 189 34] 1 C. krusei 24 1 5 [36 119 79] 48 1 [74 162 3] Fluconazole d C. parapsilosis 24 1 2 [4 55 91 15] 48 1 2 1 [42 119 41] C. krusei 24 [5 95 76 4] 48 [4 108 98 0] Voriconazole C. parapsilosis 24 [9 86 141 4] 48 [21 113 83 3] C. krusei 24 4 [17 76 139 4] 48 [0 110 125 5] Ketoconazole C. parapsilosis 24 6 [7 106 108 13] 48 2 [23 114 82 17] 2 C. krusei 24 1 10 [32 74 123 0] 48 [25 143 70] 1 Itraconazole C. parapsilosis 24 5 4 [34 129 66] 1 48 5 [28 149 57] 1 C. krusei 24 1 9 [23 68 136 3] 48 [23 170 46] Caspofungin (MK0991) C. parapsilosis 24 6 1 1 [29 159 44] 48 1 5 [11 143 67 2] 9 2 c C. krusei 24 3 [22 98 116 1] 48 4 [22 164 48] 2 Ravuconazole (BMS 207147) C. parapsilosis 24 [9 93 121 7] 10 48 3 [8 114 92 22] 1 C. krusei 24 6 10 [17 72 96 39] 48 [83 152 5] Posaconazole (SCH 56592) C. parapsilosis 24 7 [36 119 77] 1 48 1 1 [15 161 61] 1 C. krusei 24 [12 51 107 70] 48 1 [3 93 140 3] LY 303366 C. parapsilosis 24 4 3 2 [43 111 77 0] 48 1 [31 83 123 2] C. krusei 24 1 [8 130 75 23] 2 1 48 1 2 [59 108 44 14] 10 2 Open in a separate window a C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. b Proposed QC limits are indicated by brackets. c MICs outside the range of flucytosine or caspofungin that were actually tested. d Data from one laboratory were excluded because MICs of the control drug, amphotericin B, were outside of the proposed limits; another laboratory reported only 48-h readings.

Techniques: Control, Incubation

Journal:

Article Title: Synergy of Nitric Oxide and Azoles against Candida Species In Vitro

doi:

Figure Lengend Snippet: Inhibition of representative strains of Candida spp. grown in the presence of DETA-NO and DETA. Assays were performed as detailed in Materials and Methods. Percent inhibition was calculated against medium controls and represents the average of six independent experiments. Strains grown in the presence of DETA-NO are depicted by solid symbols as follows: C. albicans 4918 (•), C. krusei ATCC 30672 (★), C. parapsilosis patient isolate 9 (■), C. tropicalis ATCC 13803 (▴), C. glabrata patient isolate 15 (⧫), and C. dubliniensis patient isolate 19 (▾). Growth of each strain in the presence of DETA is indicated by the companion open symbols.

Article Snippet: The data obtained are in general agreement with the results reported in similar investigations by others ( 4 , 9 , 19 , 21 , 26 , 32 ). table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Ketoconazole Fluconazole Miconazole MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC C. albicans 4918 0.001 0.004 2.00 0.20 0.60 16.0 0.02 0.08 2.00 C. albicans patient isolate 0.001 0.005 2.00 0.06 0.12 16.0 0.04 0.20 2.00 C. albicans ATCC 28366 0.001 0.003 4.00 0.10 0.30 16.0 0.01 0.06 2.00 C. albicans ATCC 62376 0.002 0.003 3.00 0.10 0.30 18.0 0.02 0.06 2.00 C. albicans patient isolate 5 0.003 0.008 2.00 0.10 0.30 30.0 0.01 0.05 2.00 C. albicans patient isolate 27 0.001 0.004 8.00 0.10 0.30 120.0 0.02 0.06 2.00 C. krusei ATCC 30676 0.720 3.200 8.00 10.00 40.00 120.0 4.00 7.00 15.00 C. krusei patient isolate 0.900 2.200 8.00 8.00 25.00 180.0 3.50 8.00 20.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.30 1.50 6.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.50 0.60 6.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. tropicalis ATCC 13803 0.009 0.170 4.00 15.00 30.00 160.0 0.20 0.60 4.00 C. tropicalis patient isolate 0.008 0.100 4.00 15.00 50.00 180.0 0.08 0.80 2.00 C. glabrata patient isolate 0.070 0.300 15.00 2.50 10.00 180.0 0.10 0.40 6.00 C. glabrata patient isolate 0.060 0.300 20.00 2.50 10.00 120.0 0.10 0.40 2.00 C. glabrata patient isolate 0.060 0.300 12.00 2.00 7.00 80.0 0.06 0.03 2.00 C. glabrata patient isolate 0.060 0.500 20.00 7.00 22.00 200.0 0.20 0.80 8.00 C. dubliniensis patient isolate 0.001 0.007 4.00 0.40 1.00 60.0 0.03 0.80 4.00 C. dubliniensis patient isolate 0.002 0.013 2.00 0.40 1.00 60.0 0.02 0.50 2.00 Open in a separate window MICs of azoles (μg/ml) for Candida strains Synergy.

Techniques: Inhibition

Journal:

Article Title: Synergy of Nitric Oxide and Azoles against Candida Species In Vitro

doi:

Figure Lengend Snippet: MICs of DETA-NO (mg/ml) for Candida strains

Article Snippet: The data obtained are in general agreement with the results reported in similar investigations by others ( 4 , 9 , 19 , 21 , 26 , 32 ). table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Ketoconazole Fluconazole Miconazole MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC C. albicans 4918 0.001 0.004 2.00 0.20 0.60 16.0 0.02 0.08 2.00 C. albicans patient isolate 0.001 0.005 2.00 0.06 0.12 16.0 0.04 0.20 2.00 C. albicans ATCC 28366 0.001 0.003 4.00 0.10 0.30 16.0 0.01 0.06 2.00 C. albicans ATCC 62376 0.002 0.003 3.00 0.10 0.30 18.0 0.02 0.06 2.00 C. albicans patient isolate 5 0.003 0.008 2.00 0.10 0.30 30.0 0.01 0.05 2.00 C. albicans patient isolate 27 0.001 0.004 8.00 0.10 0.30 120.0 0.02 0.06 2.00 C. krusei ATCC 30676 0.720 3.200 8.00 10.00 40.00 120.0 4.00 7.00 15.00 C. krusei patient isolate 0.900 2.200 8.00 8.00 25.00 180.0 3.50 8.00 20.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.30 1.50 6.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.50 0.60 6.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. tropicalis ATCC 13803 0.009 0.170 4.00 15.00 30.00 160.0 0.20 0.60 4.00 C. tropicalis patient isolate 0.008 0.100 4.00 15.00 50.00 180.0 0.08 0.80 2.00 C. glabrata patient isolate 0.070 0.300 15.00 2.50 10.00 180.0 0.10 0.40 6.00 C. glabrata patient isolate 0.060 0.300 20.00 2.50 10.00 120.0 0.10 0.40 2.00 C. glabrata patient isolate 0.060 0.300 12.00 2.00 7.00 80.0 0.06 0.03 2.00 C. glabrata patient isolate 0.060 0.500 20.00 7.00 22.00 200.0 0.20 0.80 8.00 C. dubliniensis patient isolate 0.001 0.007 4.00 0.40 1.00 60.0 0.03 0.80 4.00 C. dubliniensis patient isolate 0.002 0.013 2.00 0.40 1.00 60.0 0.02 0.50 2.00 Open in a separate window MICs of azoles (μg/ml) for Candida strains Synergy.

Techniques:

Journal:

Article Title: Synergy of Nitric Oxide and Azoles against Candida Species In Vitro

doi:

Figure Lengend Snippet: MICs of azoles (μg/ml) for Candida strains

Article Snippet: The data obtained are in general agreement with the results reported in similar investigations by others ( 4 , 9 , 19 , 21 , 26 , 32 ). table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Ketoconazole Fluconazole Miconazole MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC C. albicans 4918 0.001 0.004 2.00 0.20 0.60 16.0 0.02 0.08 2.00 C. albicans patient isolate 0.001 0.005 2.00 0.06 0.12 16.0 0.04 0.20 2.00 C. albicans ATCC 28366 0.001 0.003 4.00 0.10 0.30 16.0 0.01 0.06 2.00 C. albicans ATCC 62376 0.002 0.003 3.00 0.10 0.30 18.0 0.02 0.06 2.00 C. albicans patient isolate 5 0.003 0.008 2.00 0.10 0.30 30.0 0.01 0.05 2.00 C. albicans patient isolate 27 0.001 0.004 8.00 0.10 0.30 120.0 0.02 0.06 2.00 C. krusei ATCC 30676 0.720 3.200 8.00 10.00 40.00 120.0 4.00 7.00 15.00 C. krusei patient isolate 0.900 2.200 8.00 8.00 25.00 180.0 3.50 8.00 20.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.30 1.50 6.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.50 0.60 6.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. tropicalis ATCC 13803 0.009 0.170 4.00 15.00 30.00 160.0 0.20 0.60 4.00 C. tropicalis patient isolate 0.008 0.100 4.00 15.00 50.00 180.0 0.08 0.80 2.00 C. glabrata patient isolate 0.070 0.300 15.00 2.50 10.00 180.0 0.10 0.40 6.00 C. glabrata patient isolate 0.060 0.300 20.00 2.50 10.00 120.0 0.10 0.40 2.00 C. glabrata patient isolate 0.060 0.300 12.00 2.00 7.00 80.0 0.06 0.03 2.00 C. glabrata patient isolate 0.060 0.500 20.00 7.00 22.00 200.0 0.20 0.80 8.00 C. dubliniensis patient isolate 0.001 0.007 4.00 0.40 1.00 60.0 0.03 0.80 4.00 C. dubliniensis patient isolate 0.002 0.013 2.00 0.40 1.00 60.0 0.02 0.50 2.00 Open in a separate window MICs of azoles (μg/ml) for Candida strains Synergy.

Techniques:

Journal:

Article Title: Synergy of Nitric Oxide and Azoles against Candida Species In Vitro

doi:

Figure Lengend Snippet: Synergy c of azoles and DETA-NO against Candida strains

Article Snippet: The data obtained are in general agreement with the results reported in similar investigations by others ( 4 , 9 , 19 , 21 , 26 , 32 ). table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Ketoconazole Fluconazole Miconazole MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC MIC 50 MIC 80 MIC C. albicans 4918 0.001 0.004 2.00 0.20 0.60 16.0 0.02 0.08 2.00 C. albicans patient isolate 0.001 0.005 2.00 0.06 0.12 16.0 0.04 0.20 2.00 C. albicans ATCC 28366 0.001 0.003 4.00 0.10 0.30 16.0 0.01 0.06 2.00 C. albicans ATCC 62376 0.002 0.003 3.00 0.10 0.30 18.0 0.02 0.06 2.00 C. albicans patient isolate 5 0.003 0.008 2.00 0.10 0.30 30.0 0.01 0.05 2.00 C. albicans patient isolate 27 0.001 0.004 8.00 0.10 0.30 120.0 0.02 0.06 2.00 C. krusei ATCC 30676 0.720 3.200 8.00 10.00 40.00 120.0 4.00 7.00 15.00 C. krusei patient isolate 0.900 2.200 8.00 8.00 25.00 180.0 3.50 8.00 20.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.30 1.50 6.00 C. parapsilosis patient isolate 0.005 0.020 0.08 0.20 0.40 2.0 0.50 0.60 6.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. parapsilosis patient isolate 0.004 0.010 0.08 0.20 0.40 2.0 0.10 0.50 2.00 C. tropicalis ATCC 13803 0.009 0.170 4.00 15.00 30.00 160.0 0.20 0.60 4.00 C. tropicalis patient isolate 0.008 0.100 4.00 15.00 50.00 180.0 0.08 0.80 2.00 C. glabrata patient isolate 0.070 0.300 15.00 2.50 10.00 180.0 0.10 0.40 6.00 C. glabrata patient isolate 0.060 0.300 20.00 2.50 10.00 120.0 0.10 0.40 2.00 C. glabrata patient isolate 0.060 0.300 12.00 2.00 7.00 80.0 0.06 0.03 2.00 C. glabrata patient isolate 0.060 0.500 20.00 7.00 22.00 200.0 0.20 0.80 8.00 C. dubliniensis patient isolate 0.001 0.007 4.00 0.40 1.00 60.0 0.03 0.80 4.00 C. dubliniensis patient isolate 0.002 0.013 2.00 0.40 1.00 60.0 0.02 0.50 2.00 Open in a separate window MICs of azoles (μg/ml) for Candida strains Synergy.

Techniques: